Rapport Therapeutics Raises $150 Million In Series B Funding Round And Announces Key Board Appointments To Further Advance Precision Neuromedicine Platform
Amount Raised
$150 Million
Round Type
Series B
United StatesInformation TechnologyBiotechnologyHealth CareTherapeuticsInvestors
Description
Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced that it has raised $150 million in Series B funding. Led by Cormorant Asset Management, the round includes investments from Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., and all existing investors, which include Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC, Inc. (JJDC).
Quick answer
Rapport raised $150 Million in a Series B round, dated August 24, 2023. Investors: James Healy, M.D., Ph.D., Managing Partner Of Sofinnova Investments, Rapport, Johnson & Johnson Innovation – JJDC, ARCH Venture Partners, Third Rock Ventures, T. Rowe Price Associates, Surveyor Capital and Sofinnova Investments. Rapport is based in United States.
- How much did Rapport raise?
- Rapport raised $150 Million in a Series B round on August 24, 2023.
- Who invested in Rapport?
- James Healy, M.D., Ph.D., Managing Partner Of Sofinnova Investments, Rapport, Johnson & Johnson Innovation – JJDC, ARCH Venture Partners, Third Rock Ventures, T. Rowe Price Associates, Surveyor Capital and Sofinnova Investments are named as investors in this round.
- What does Rapport do?
- (www.rapportrx.com) Rapport pursues precision neuromedicine in an effort to give patients better alternatives to current treatments for neurological diseases, which often come with reduced efficacy and side effects that..
- Where is Rapport based and how big is it?
- Rapport is based in United States.
- Who are the decision-makers at Rapport?
- Fundz holds 1 contact at Rapport. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Rapport that raised within 45 days of this round, from Fundz verified event records.
- Amicus Therapeutics raised an undisclosed amount (Funding Round) on October 2, 2023.
- Acasti raised $7.5M (Post-IPO Equity) on September 26, 2023.
- Acasti raised $7.5M on September 25, 2023.
- Qihan Biotech raised an undisclosed amount (Series B) on September 23, 2023.
- DalCor Pharmaceuticals raised $80M (Series D) on September 13, 2023.
- Renibus Therapeutics raised an undisclosed amount (Series B) on September 12, 2023.
Who to call at Rapport, and when
A new round usually means Rapport is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Rapport raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rapport, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rapport. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rapport raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRapport raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.